Stockreport

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Prelude Therapeutics Incorporated  (PRLD) 
PDF Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses P [Read more]